FDA ApprovedA Targeted FDA Approval in Prostate Cancer: Green Light for the Capivasertib + Abiraterone Combination!The FDA approved capivasertib (Truqap) in combination with abiraterone and prednisone for PTEN-deficient metastatic (androgen pathway modulation–naïve/–sensitive) prostate cancer, as determined by an FDA-authorized test.June 18, 2026
FDA ApprovedAn Important FDA Approval in Ovarian Cancer: Green Light for the Relacorilant + Nab-Paclitaxel Combination!The FDA approved the glucocorticoid receptor antagonist relacorilant in combination with nab-paclitaxel for previously treated platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer.June 16, 2026
FDA ApprovedA Breakthrough FDA Approval in Kidney Cancer: Green Light for the Belzutifan + Pembrolizumab Combination!The FDA approved the belzutifan + pembrolizumab combination as adjuvant (post-surgery) therapy for clear cell renal cell carcinoma (ccRCC) patients at high risk of recurrence.June 15, 2026
Prof. Dr. Mutlu DemirayMedical OncologyProf. Dr. Mutlu DemirayMedical Oncology